Format

Send to

Choose Destination
Immunotherapy. 2016 Jun;8(6):687-92. doi: 10.2217/imt-2015-0025. Epub 2016 Apr 26.

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Author information

1
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.
2
Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
3
Dermatology Department, Hospital Clinic Barcelona, Barcelona, Spain.
4
CIBER Enfermedades Raras, Instituto de Salud Carlos III, Spain, Madrid, Spain.
5
University of Barcelona, Barcelona, Spain.

Abstract

Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis and was subsequently treated with the anti-programmed cell death 1 protein (PD-1) antibody pembrolizumab. He has been on treatment with pembrolizumab for more than 20 months with no major toxicities and has achieved an objective partial response, which is ongoing.

KEYWORDS:

anti-CTLA-4; anti-PD-1; immune-related adverse event; melanoma

PMID:
27115320
DOI:
10.2217/imt-2015-0025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center